246 related articles for article (PubMed ID: 34521447)
1. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
Langman CB
Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
[TBL] [Abstract][Full Text] [Related]
4. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
5. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
[TBL] [Abstract][Full Text] [Related]
6. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
Medic G; van der Weijden M; Karabis A; Hemels M
Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
8. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
[TBL] [Abstract][Full Text] [Related]
9. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
10. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
[TBL] [Abstract][Full Text] [Related]
11. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
12. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
14. Cystinosis: a new perspective.
Veys KR; Besouw MT; Pinxten AM; Dyck MV; Casteels I; Levtchenko EN
Acta Clin Belg; 2016 Jun; 71(3):131-7. PubMed ID: 25560059
[TBL] [Abstract][Full Text] [Related]
15. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
Dohil R; Cabrera BL
Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
[TBL] [Abstract][Full Text] [Related]
18. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
19. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
[TBL] [Abstract][Full Text] [Related]
20. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
